Expression of Encoding Novel ROR1 Binding Partner is Robust Predictor of Survival in Chronic Lymphocytic Leukemia

Overview

Journal Haematologica

Specialty Hematology

Date 2017 Nov 11

PMID 29122990

Citations 13

Authors

Hana Plesingerova

Pavlina Janovska

Archana Mishra

Lucie Smyckova

Lucie Poppova

Antonin Libra

Karla Plevova

Petra Ovesna

Lenka Radova

Michael Doubek

Sarka Pavlova

Sarka Pospisilova

Vitezslav Bryja

Affiliations

Soon will be listed here.

Abstract

Chronic lymphocytic leukemia is a disease with up-regulated expression of the transmembrane tyrosine-protein kinase ROR1, a member of the Wnt/planar cell polarity pathway. In this study, we identified COBLL1 as a novel interaction partner of ROR1. shows clear bimodal expression with high levels in chronic lymphocytic leukemia patients with mutated IGHV and approximately 30% of chronic lymphocytic leukemia patients with unmutated IGHV. In the remaining 70% of chronic lymphocytic leukemia patients with unmutated IGHV, expression is low. Importantly, chronic lymphocytic leukemia patients with unmutated IGHV and high have an unfavorable disease course with short overall survival and time to second treatment. serves as an independent molecular marker for overall survival in chronic lymphocytic leukemia patients with unmutated IGHV. In addition, chronic lymphocytic leukemia patients with unmutated IGHV and high show impaired motility and chemotaxis towards CCL19 and CXCL12 as well as enhanced B-cell receptor signaling pathway activation demonstrated by increased PLCγ2 and SYK phosphorylation after IgM stimulation. expression also changes during B-cell maturation in non-malignant secondary lymphoid tissue with a higher expression in germinal center B cells than naïve and memory B cells. Our data thus suggest involvement not only in chronic lymphocytic leukemia but also in B-cell development. In summary, we show that expression of , encoding novel ROR1-binding partner, defines chronic lymphocytic leukemia subgroups with a distinct response to microenvironmental stimuli, and independently predicts survival of chronic lymphocytic leukemia with unmutated IGHV.

Citing Articles

SP140 represses specific loci by recruiting polycomb repressive complex 2 and NuRD complex.

Tamburri S, Zucchelli C, Matafora V, Zapparoli E, Jevtic Z, Farris F Nucleic Acids Res. 2024; 53(4).

PMID: 39718989 PMC: 11879014. DOI: 10.1093/nar/gkae1215.

Zebrafish regulates lipid homeostasis via the RA signaling pathway.

Zeng T, Lv J, Liang J, Xie B, Liu L, Tan Y Front Cell Dev Biol. 2024; 12:1381362.

PMID: 38699158 PMC: 11063382. DOI: 10.3389/fcell.2024.1381362.

ARPC5 is transcriptionally activated by KLF4, and promotes cell migration and invasion in prostate cancer via up-regulating ADAM17 : ARPC5 serves as an oncogene in prostate cancer.

Qu G, Zhang Y, Duan H, Tang C, Yang G, Chen D Apoptosis. 2023; 28(5-6):783-795.

PMID: 36881291 DOI: 10.1007/s10495-023-01827-3.

An in vitro approach to understand contribution of kidney cells to human urinary extracellular vesicles.

Barreiro K, Lay A, Leparc G, Tran V, Rosler M, Dayalan L J Extracell Vesicles. 2023; 12(2):e12304.

PMID: 36785873 PMC: 9925963. DOI: 10.1002/jev2.12304.

Insight into genetic, biological, and environmental determinants of sexual-dimorphism in type 2 diabetes and glucose-related traits.

Lamri A, De Paoli M, de Souza R, Werstuck G, Anand S, Pigeyre M Front Cardiovasc Med. 2022; 9:964743.

PMID: 36505380 PMC: 9729955. DOI: 10.3389/fcvm.2022.964743.

References

Hamblin T, Davis Z, Oscier D . Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia - long-term follow up of patients with different percentages of mutations. Br J Haematol. 2007; 140(3):320-3. DOI: 10.1111/j.1365-2141.2007.06928.x. View

Baskar S, Kwong K, Hofer T, Levy J, Kennedy M, Lee E . Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2008; 14(2):396-404. DOI: 10.1158/1078-0432.CCR-07-1823. View

Kaucka M, Krejci P, Plevova K, Pavlova S, Prochazkova J, Janovska P . Post-translational modifications regulate signalling by Ror1. Acta Physiol (Oxf). 2011; 203(3):351-62. DOI: 10.1111/j.1748-1716.2011.02306.x. View

Morabito F, Cutrona G, Gentile M, Fabbi M, Matis S, Colombo M . Prognostic relevance of in vitro response to cell stimulation via surface IgD in binet stage a CLL. Br J Haematol. 2009; 149(1):160-3. DOI: 10.1111/j.1365-2141.2009.08032.x. View

Rosenwald A, Alizadeh A, Widhopf G, Simon R, Davis R, Yu X . Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001; 194(11):1639-47. PMC: 2193523. DOI: 10.1084/jem.194.11.1639. View

Janovska P, Poppova L, Plevova K, Plesingerova H, Behal M, Kaucka M . Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2015; 22(2):459-69. PMC: 4716000. DOI: 10.1158/1078-0432.CCR-15-0154. View

Han S, Kim S, Kim H, Lee Y, Choi S, Park G . Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia. Leukemia. 2017; 31(7):1532-1539. DOI: 10.1038/leu.2017.72. View

Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro J . Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A. 2008; 105(8):3047-52. PMC: 2268582. DOI: 10.1073/pnas.0712148105. View

Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D . Circos: an information aesthetic for comparative genomics. Genome Res. 2009; 19(9):1639-45. PMC: 2752132. DOI: 10.1101/gr.092759.109. View

10.

Kotaskova J, Pavlova S, Greif I, Stehlikova O, Plevova K, Janovska P . ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells. Br J Haematol. 2015; 175(2):339-342. DOI: 10.1111/bjh.13848. View

11.

Paganoni S, Ferreira A . Neurite extension in central neurons: a novel role for the receptor tyrosine kinases Ror1 and Ror2. J Cell Sci. 2005; 118(Pt 2):433-46. PMC: 1351101. DOI: 10.1242/jcs.01622. View

12.

Palomba M, Piersanti K, Ziegler C, Decker H, Cotari J, Bantilan K . Multidimensional single-cell analysis of BCR signaling reveals proximal activation defect as a hallmark of chronic lymphocytic leukemia B cells. PLoS One. 2014; 9(1):e79987. PMC: 3906024. DOI: 10.1371/journal.pone.0079987. View

13.

Khan A, Hojjat-Farsangi M, Daneshmanesh A, Hansson L, Kokhaei P, Osterborg A . Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia. Tumour Biol. 2016; 37(9):11947-11957. DOI: 10.1007/s13277-016-5039-5. View

14.

Arquint C, Sonnen K, Stierhof Y, Nigg E . Cell-cycle-regulated expression of STIL controls centriole number in human cells. J Cell Sci. 2012; 125(Pt 5):1342-52. DOI: 10.1242/jcs.099887. View

15.

Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater A . ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia. 2012; 26(7):1458-61. DOI: 10.1038/leu.2012.25. View

16.

Baliakas P, Hadzidimitriou A, Sutton L, Minga E, Agathangelidis A, Nichelatti M . Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. Lancet Haematol. 2016; 1(2):e74-84. DOI: 10.1016/S2352-3026(14)00005-2. View

17.

Thompson P, OBrien S, Wierda W, Ferrajoli A, Stingo F, Smith S . Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015; 121(20):3612-21. PMC: 4866653. DOI: 10.1002/cncr.29566. View

18.

Gordon G, Jensen R, Hsiao L, Gullans S, Blumenstock J, Richards W . Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst. 2003; 95(8):598-605. DOI: 10.1093/jnci/95.8.598. View

19.

Bryja V, Schulte G, Arenas E . Wnt-3a utilizes a novel low dose and rapid pathway that does not require casein kinase 1-mediated phosphorylation of Dvl to activate beta-catenin. Cell Signal. 2006; 19(3):610-6. DOI: 10.1016/j.cellsig.2006.08.011. View

20.

Malcikova J, Smardova J, Rocnova L, Tichy B, Kuglik P, Vranova V . Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood. 2009; 114(26):5307-14. DOI: 10.1182/blood-2009-07-234708. View